Johnson & Johnson’s Cerenovus recently announced it has launched its new stroke solutions platform that includes three devices for clot removal procedures.
The three devices are designed to aid physicians in performing mechanical thrombectomy procedures. The devices include the Cerebase DA Guide Sheath, Cerenovus Large Bore Catheter and Embotrap III Revascularization Device.
Cerebase DA Guide Sheath is a long guide sheath that is designed with more traceability to allow physicians to navigate challenging anatomy and secure distal access for geometric anchoring.
The Cerenovus Large Bore Catheter is designed for atraumatic vessel wall interaction to balance traceability with more durability and compatibility. It has distal kink resistance in a thin wall design, according to the company, and allows for rapid navigation to the middle cerebral artery based on anatomically optimized design.
Johnson & Johnson’s Embotrap III Revascularization Device is a stent retriever that is designed to engage a wide range of clot types and provide more tailored options to achieve the first pass effect, which is an independent predictor of good functional outcome and can result in faster patient recovery times.
“Not all mechanical thrombectomy procedures are equal and the greatest benefits to patients are observed when reperfusion is achieved from the first pass,” Kyriakos Lobotesis, the principal investigator on the company’s “Excellent” study of the device, said in a news release. “The Excellent registry is a unique study that goes beyond reporting patient outcomes and helps to understand more about clot composition, revascularization rates and clinical outcomes.”
Strokes are the second leading cause of death globally, according to Johnson & Johnson. Over half of stroke survivors become chronically disabled and place an estimated $34 billion in economic burden on the U.S. healthcare system each year.
“Stroke is a silent killer that can take a life within minutes, and we designed Cerenovus Stroke Solutions to support physicians in successfully treating their patients efficiently and effectively,” said Mark Dickinson, worldwide president for Cerenovus. “We are committed to developing differentiated solutions based on physicians’ real-world experiences to change the trajectory of stroke care.”
Each device has received FDA 510(k) clearance and CE mark approval and is currently on the market and available in the U.S. and Europe.